MAP2K7 and glioblastoma: Compound 27 was shown at 300 μM to inhibit p-Akt (inhibition rate ~ 34%) and p-ERK1/2 (inhibition rate ~ 40%) protein expression in vitro, and the determinants of anti-proliferation and migration effects against glioblastoma U251 cells (IC50 = 287.1 ± 1.0 μM) in vitro included TRPM7-regulated PI3K/Akt and MEK/ERK signaling [48].